Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Masitinib - AB Science

X
Drug Profile

Masitinib - AB Science

Alternative Names: AB-07105; AB-1010; Alsitek; Masican; Masipro; Masitinib mesilate; Masitinib mesylate; Masiviera

Latest Information Update: 04 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AB Science
  • Class Anti-inflammatories; Antiasthmatics; Antidementias; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antirheumatics; Antivirals; Benzamides; Mood stabilisers; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor inhibitors; Coronavirus-3C-like-proteinase inhibitors; Endopeptidase Clp inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor modulators; Mast cell inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-fyn modulators; Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mastocytosis; Amyotrophic lateral sclerosis; Gastric cancer; Gastrointestinal stromal tumours; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis
  • Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Mastocytosis; Multiple myeloma; Multiple sclerosis; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
  • Phase II/III Crohn's disease; Ovarian cancer
  • Phase II Breast cancer; Chronic obstructive pulmonary disease; COVID 2019 infections; Head and neck cancer; Non-small cell lung cancer; Parkinson's disease
  • Phase I/II Gastric cancer; Glioblastoma; Liver cancer; Oesophageal cancer
  • No development reported Psoriasis; Stroke
  • Discontinued Malignant melanoma; Mood disorders; Progressive supranuclear palsy; Rheumatoid arthritis

Most Recent Events

  • 29 May 2024 AB Science expects formal opinion from CHMP on marketing authorisation application of masitinib for Amyotrophic lateral sclerosis in June 2024
  • 29 May 2024 The CHMP adopts trending toward negative opinion on MAA for Amyotrophic lateral sclerosis
  • 03 Apr 2024 Health Canada grants eligibility for reconsideration request for masitinib in Amyotrophic lateral sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top